Regular Article
Corticotropin-Releasing Hormone Protects Neurons against Insults Relevant to the Pathogenesis of Alzheimer's Disease

https://doi.org/10.1006/nbdi.2001.0395Get rights and content

Abstract

We previously reported that mice over-expressing the human amyloid precursor protein gene with the double Swedish mutation of familial Alzheimer's disease (mtAPP), which exhibit progressive deposition of amyloid β-peptide in hippocampal and cortical brain regions, have an impaired ability to maintain a sustained glucocorticoid response to stress. Corticotropin releasing hormone (CRH), which initiates neuroendocrine responses to stress by activating the hypothalamic—pituitary—adrenal (HPA) axis, is expressed in brain regions prone to degeneration in Alzheimer's disease. We therefore tested the hypothesis that CRH can modify neuronal vulnerability to amyloid β-peptide toxicity. In primary neuronal culture, CRH was protective against cell death caused by an amyloid-β peptide, an effect that was blocked by a CRH receptor antagonist and by an inhibitor of cyclic AMP-dependent protein kinase. The increased resistance of CRH-treated neurons to amyloid toxicity was associated with stabilization of cellular calcium homeostasis. Moreover, CRH protected neurons against death caused by lipid peroxidation and the excitotoxic neurotransmitter glutamate. The level of mRNA encoding CRH was unchanged in mtAPP mouse brain, whereas the levels of mRNAs encoding glucocorticoid and mineralocorticoid receptors were subtly altered. Our results suggest that disturbances in HPA axis function can occur independently of alterations in CRH mRNA levels in Alzheimer's disease brain and further suggest an additional role for CRH in protecting neurons against cell death.

References (65)

  • M.K. Lyons et al.

    Corticotropin releasing factor antagonist reduces ischemic hippocampal neuronal injury

    Brain Res.

    (1991)
  • H. Maecker et al.

    Astressin, a novel and potent CRF antagonist, is neuroprotective in the hippocampus when administered after a seizure

    Brain Res.

    (1997)
  • R.S. Mansbach et al.

    Antidepressant-like effects of CP-154,526, a selective CRF1 receptor antagonist

    Eur. J. Pharmacol.

    (1997)
  • M.I. Morano et al.

    The role of the hippocampal mineralocorticoid and glucocorticoid receptors in the hypothalamo-pituitary-adrenal axis of the aged Fisher rat

    Mol. Cell. Neurosci.

    (1994)
  • S.M. Morin et al.

    Differential distribution of urocortin- and corticotropin-releasing factor-like immunoreactivities in the rat brain

    Neuroscience

    (1999)
  • B. Näsman et al.

    Blunted adrenocorticotropin and increased adrenal steroid response to human corticotropin-releasing hormone in Alzheimer's disease

    Biol. Psychiatry

    (1996)
  • W.A. Pedersen et al.

    The lipid peroxidation product 4-hydroxynonenal impairs glutamate and glucose transport and choline acetyltransferase activity in NSC-19 motor neuron cells

    Exp. Neurol.

    (1999)
  • D.T. Piekut et al.

    Increased corticotropin-releasing factor immunoreactivity in select brain sites following kainate-elicited seizures

    Brain Res.

    (1998)
  • N. Pomara et al.

    CSF corticotropin-releasing factor (CRF) in Alzheimer's disease: Its relationship to severity of dementia and monoamine metabolites

    Biol. Psychiatry

    (1989)
  • J.M. Reul et al.

    Age-related changes in the dog hypothalamic-pituitary-adrenocortical system: Neuroendocrine activity and corticosteroid receptors

    J. Steroid Biochem. Mol. Biol.

    (1991)
  • G.W. Smith et al.

    Corticotropin releasing factor receptor 1-deficient mice display decreased anxiety, impaired stress response, and aberrant neuroendocrine development

    Neuron

    (1998)
  • P.J.L.M. Strijbos et al.

    Corticotrophin-releasing factor antagonist inhibits neuronal damage induced by focal cerebral ischemia or activation of NMDA receptors in the rat brain

    Brain Res.

    (1994)
  • J.A. van Eekelen et al.

    Brain corticosteroid receptor gene expression and neuroendocrine dynamics during aging

    J. Steroid Biochem. Mol. Biol.

    (1991)
  • M.F. Weiner et al.

    Cortisol secretion and Alzheimer's disease progression

    Biol. Psychiatry

    (1997)
  • L. Arborelius et al.

    The role of corticotropin-releasing factor in depression and anxiety disorders

    J. Endocrinol.

    (1999)
  • D.P. Behan et al.

    Displacement of corticotropin releasing factor from its binding protein as a possible treatment for Alzheimer's disease

    Nature

    (1995)
  • D.P. Behan et al.

    Corticotropin-releasing factor (CRF), CRF-binding protein (CRF-BP), and CRF/CRF-BP complex in Alzheimer's disease and control postmortem human brain

    J. Neurochem.

    (1997)
  • P.F. Chapman et al.

    Impaired synaptic plasticity and learning in aged amyloid precursor protein transgenic mice

    Nat. Neurosci.

    (1999)
  • Y.L. Chen et al.

    Synthesis and oral efficacy of a 4-(butylethylamino)pyrrolo[2,3-d]pyrimidine: A centrally active corticotropin-releasing factor1 receptor antagonist

    J. Med. Chem.

    (1997)
  • G. Chen et al.

    A learning deficit related to age and β-amyloid plaques in a mouse model of Alzheimer's disease

    Nature

    (2000)
  • D.H. Chui et al.

    Transgenic mice with Alzheimer presenilin 1 mutations show accelerated neurodegeneration without amyloid plaque formation

    Nat. Med.

    (1999)
  • S.C. Coste et al.

    Abnormal adaptations to stress and impaired cardiovascular function in mice lacking corticotropin-releasing hormone receptor-2

    Nat. Genet.

    (2000)
  • Cited by (0)

    View full text